D
Duke University Health System | Duke Gastroenterology Clinic - Clinic 2
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Ifinatamab
Lurbinectedin
Topotecan
Amrubicin
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 3 total trials
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lun...
Enrolling
Small Cell Lung Cancer
Drug: Topotecan
Drug: Amrubicin
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that tar...
Enrolling
Relapsed/Refractory Multiple Myeloma
Biological: CB-011
This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics...
Active, not recruiting
Extensive-stage Small-cell Lung Cancer
Drug: Ifinatamab Deruxtecan (I-DXd)
Trial sponsors
C
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems